State-of-the art treatment of multiple myeloma (MM) involves induction with triplet-based regimens using combinations of immunomodulatory drugs and proteasome inhibitors, which have shown improved progression-free survival and overall survival compared with doublet regimens in the newly diagnosed (ND) and relapsed and refractory (RR) setting.1-3 Carfilzomib is a selective proteasome inhibitor approved by the US Food and Drug Administration for use in the carfilzomib, lenalidomide, and dexamethasone (KRd) regimen for the treatment of RRMM.3,4 We previously reported early data on this phase 2 study of 45 patients with NDMM.5 Herein, we expand on our initial results and present the long-term durability of minimal residual disease–negative complete remissions (MRD-negative CRs) and time to progression, the last characterized by depth of response, age, and cytogenetic risk profile.
Kazandjian D, Korde N, Mailankody S, et al. Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial. JAMA Oncol. 2018;4(12):1781–1783. doi:10.1001/jamaoncol.2018.5457
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: